We are inspiring human belief in a healthier world
Our founding mission is to make highly quality medicines affordable and accessible to the world
30 years of Service in the pharmaceutical industry, backed by proven track record in R&D excellence
Our mission to enable access to affordable medicines and improve lives flow from the top
Expanding our presence to serve more people and create meaningful impact
Being acknowledged for our efforts motivates our entire team
Our expertise across APIs, global generics, biosimilars and custom pharmaceutical services is secured by a strong R&D backbone
We have steadily invested in a wide range of innovations to make our product portfolio diverse and differentiated in a competitive market
The path to serving patients better
World-class and differentiated portfolio in chronic therapy areas
Achieving a sustainable health equity
Fully integrated services across the value chain
Committed to transforming standards of care
Researching areas of unmet medical need
Our expertise rest on the pillars of our advanced R&D capabilities, world-class manufacturing facilities, our long legacy of trust and our partnerships
Research excellence for us means to invest in the future of health for the world
We invest in cutting edge research to develop new cures for challenging diseases
Built to world-class standards, our facilities enable us to produce high-quality and affordable medicines
Legacy of trust
Growing better, together
We are committed to making a positive impact by contributing to healthy communities and leading a responsible business
Aiming for a sustainable environment
A constant focus on sustainable environment with focus on health and safety
A steadfast commitment to enable communities
Hetero aims to report comprehensively and transparently for all stakeholders
Find range of resources including press releases, featured stories and information on social media channels
Access our latest press releases and resources for News and Media section
Discover the stories that enumerate the way we understand disease and develop medicines
Latest media releases and statements in the Hetero newsroom
Browse and download multimedia resources for use
Notices
Back
India, Hyderabad, December 14th, 2015: Hetero, one of Indiaâs leading generic pharmaceutical companies and one of the worldâs largest producer of anti-retroviral drugs, today announced that it has received the approval from Drug Controller General of India (DCGI) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.
This product is a generic version of Bristol-Myers Squibbâs brand âDaklinzaâ - approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment. 1 Research studies indicates that this drug enables the rapid decline of Hepatitis C virus.2 3 Daclatasvir is included the World Health Organizationâs List of Essential medicines.4
About Hetero
Hetero is one of Indiaâs leading generic pharmaceutical companies and is one of the worldâs largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. With more than 20 years of expertise in the pharmaceutical industry, Heteroâs strategic business areas include APIs, generics and biosimilars. Hetero also offers custom pharmaceutical services to its partners around the world. The company is recognized for its strengths in Research & Development, manufacturing and commercialization of a wide range of products
Hetero has more than 25 state-of-the-art manufacturing facilities strategically located worldwide. Majority of our facilities have been successfully audited and approved by various regulatory authorities like US-FDA, EU, TGA â Australia, MCC â South Africa and others. Our portfolio includes more than 200 products, encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, etc.
Hetero has a strong global presence in over 120 countries and focusses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com.
Media Contact:
Jeyasingh Balakrishnan Head â Corporate Communications Hetero Labs Limited, India Mobile: +91 9989626541/ +91 9833836185 Email: Jeyasingh.b@heterodrugs.com